Results 221 to 230 of about 288,179 (287)
Objective A leading cause of death among scleroderma (SSc) patients, interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool.
Cristina M Padilla +13 more
wiley +1 more source
Salicylic acid and jasmonic acid in plant immunity. [PDF]
Zhang P, Jackson E, Li X, Zhang Y.
europepmc +1 more source
Introduction There are no Food and Drug Administration (FDA) approved therapies for Raynaud's phenomenon (RP) treatment in the United States (U.S.). Clinical trials have been challenged by study design. Important advances in RP patient reported outcome measures and mechanistic quantification allows RP‐related pain characterization.
Tracy M Frech +4 more
wiley +1 more source
Phytophthora Avr3a-Like Effectors Target and Inhibit Cinnamyl Alcohol Dehydrogenase CAD5 to Suppress Plant Immunity. [PDF]
Li L +10 more
europepmc +1 more source
Beyond Inflammation: Why Understanding the Brain Matters in Inflammatory Arthritis
Persistent pain remains a major challenge in inflammatory arthritis, even when joint inflammation is well controlled. Pain and associated symptoms such as fatigue cannot be explained by peripheral inflammation alone but reflect altered central pain processing. These changes may arise through “top‐down” mechanisms, reflecting pre‐existing dysfunction in
Eoin M. Kelleher +2 more
wiley +1 more source
The Nucleoporin CPR5 Modulates Plant Immunity via Guanylate-Binding Proteins. [PDF]
Pan L +8 more
europepmc +1 more source
Genetic Dissection and Functional Analysis of a Putative Lipase in Plant Immunity
Chenglong Liu
openalex +1 more source
Objectives Sjögren's disease is an autoimmune disorder that can impact multiple organ systems, including the peripheral nervous system (PNS). PNS manifestations, which can exist concurrently, include mononeuropathies, polyneuropathies, and autonomic nervous system neuropathies. To help patients and providers in the decision‐making process, we developed
Anahita Deboo +19 more
wiley +1 more source

